VIVUS

Executive Summary

VIVUS is a U.S.-based biopharmaceutical company founded in 1991 and headquartered in Campbell, California. The company specializes in developing and commercializing therapies for serious medical conditions, with a current portfolio focused on exocrine pancreatic insufficiency (EPI) and obesity management. Leveraging its clinical development expertise, VIVUS has established a presence in specialty markets through products like PANCREAZE for EPI and Qsymia for obesity. As a private company, VIVUS continues to invest in its pipeline to address unmet needs in these therapeutic areas, aiming to capture additional market share and drive growth through potential label expansions and new product candidates. Looking ahead, VIVUS is expected to pursue clinical and regulatory advancements to strengthen its product lineup. Key upcoming catalysts include the potential approval of a once-daily formulation of its obesity therapy, which could improve patient adherence and expand the addressable population. Additionally, the company may report topline data from a Phase 3 trial evaluating a next-generation pancreatic enzyme replacement therapy, offering enhanced efficacy for EPI patients. Finally, VIVUS might explore strategic partnerships or licensing agreements to accelerate development and commercialization, particularly in international markets. These catalysts, if successful, could significantly enhance VIVUS's competitive positioning and financial outlook.

Upcoming Catalysts (preview)

• Q3 2026FDA approval decision for once-daily obesity therapy70% success
• Q4 2026Phase 3 topline data for next-generation EPI product65% success
• Q2 2026Strategic partnership or licensing deal for international expansion60% success